Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 4/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869138 | 0.89 | XDH (0.35) | XDHMKNK1MKNK2 | |
| SCHEMBL870934 | 0.88 | XDH (0.45) | XDHMKNK1MKNK2 | |
| SCHEMBL11985268 | 0.86 | MKNK1 (0.34) | XDHMKNK1MKNK2 | |
| SCHEMBL10182185 | 0.86 | KMO (0.41) | XDHMKNK1MKNK2 | |
| SCHEMBL871636 | 0.85 | KAT6A (0.40) | XDHMKNK1MKNK2 | |
| SCHEMBL11985203 | 0.85 | KAT6A (0.40) | XDHMKNK1MKNK2 | |
| SCHEMBL871880 | 0.84 | SCN10A (0.40) | XDHMKNK1MKNK2 | |
| SCHEMBL871066 | 0.84 | XDH (0.45) | XDHMKNK1MKNK2 | |
| SCHEMBL11985204 | 0.84 | SCN10A (0.40) | XDHMKNK1MKNK2 | |
| SCHEMBL871769 | 0.78 | PIP4K2A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120207810-A1 | Kinase Inhibitors | SPADA LON T (US) | 2012-08-16 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | XDH 2732/4885MCL1 1259/4885ACMSD 4672/4885 |
| US-20120207810-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | XDH 2732/4885MCL1 1259/4885ACMSD 4672/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | XDH 2732/4885MCL1 1259/4885ACMSD 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.